Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib

Clinical Cancer Research

Volumn 15, Issue 2, 2009, Pages 578-588

  Ma, Jie ^a   Waxman, David J ^a  

^a Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; AXITINIB; CYCLOPHOSPHAMIDE; DRUG METABOLITE; FLUORESCENT DYE; HOE 33342; PIMONIDAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG UPTAKE; GLIOSARCOMA; HUMAN; HUMAN CELL; HYPOXIA; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; STAINING; TUMOR CELL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VASCULAR PATENCY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; GENES, DOMINANT; HUMANS; IMIDAZOLES; INDAZOLES; MALE; MICE; MICE, INBRED ICR; MICE, SCID; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS;

EID: 59449106047     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1174     Document Type: Article

References (48)

1. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev 2007;6:273-86.
2. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006; 312:1171 -5.
3. Gasparini G, Longo R, Fanelli M.Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 2005;23:1295-311.
4. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-63.
5. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731 -6.
6. Wildiers H, Guetens G, De Boeck G, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003; 88:1979-86.
7. Dickson PV, Hamner JB, SimsTL, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007;13:3942-50.
8. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
9. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40.
10. Manley PW, Bold G, Bruggen J, et al. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim Biophys Acta 2004;1697:17-27.
11. Lee S, ChenTT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007; 130:691-703.
12. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
13. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
14. Paul S, Foutz T, Calleri A, et al. AG-013736, a potent VEGF/PDGF receptor tyrosine kinase inhibitor, is active against lymphoma growth and chemotherapy-induced vasculogenesis. Blood 2003;102:649a.
15. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006;313: 1785-7.
16. Wickman G, Hallin M, Dillon R, et al. Further characterization of the potent VEGF/PDGF receptor tyrosine kinase inhibitor, AG-013736, in preclinical tumor models for its antiangiognesis and antitumor activity. In: AACR 94th Annual Meeting; 2003 Jul 11-14; Washington, DC. p. A3780.
17. George DJ. Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma. Clin Cancer Res 2007;13:753-7s.
18. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007;8:975-84.
19. m cyclophosphamide 4- hydroxylase P450 2B11. Mol Cancer Ther 2006;5: 541 -55.
20. Chen CS, Jounaidi Y, Su T, Waxman DJ. Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model. Cancer GeneTher 2007; 14:935-44.
21. Ma J, Waxman DJ. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol Cancer Ther 2008;7: 79-89.
22. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
23. Jounaidi Y, Waxman DJ. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy. Cancer Res 2001; 61:4437-44.
24. Ma J, Waxman DJ. Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment. Mol Cancer Ther 2007;6:2879-90.
25. Franco M, Man S, Chen L, et al. Targeted antivascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 2006;66:3639-48.
26. Yu LJ, Drewes P, Gustafsson K, Brain EGC, Hecht JED, Waxman DJ. In vivo modulation of alternative pathways of P450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity. J Pharmacol Exp Ther 1999;288:928-37.
27. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006;290:H560-76.
28. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165: 35-52.
29. Braun RD, Lanzen JL, Snyder SA, Dewhirst MW. Comparison of tumor and normal tissue oxygen tension measurements using OxyLite or microelectrodes in rodents. Am J Physiol Heart Circ Physiol 2001;280: H2533-44.
30. Swartz HM, Khan N, Buckey J, et al. Clinical applications of EPR: overview and perspectives. NMR Biomed 2004;17:335-51.
31. Lord EM, Harwell L, Koch CJ. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimi-dazole adducts. Cancer Res 1993;53:5721 -6.
32. Gross MW, Karbach U, Groebe K, Franko AJ, Mueller-KlieserW. Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids. Int J Cancer 1995;61:567-73.
33. Emmenegger U, Morton GC, Francia G, et al. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res 2006;66:1664- 74.
34. Ansiaux R, Baudelet C, Jordan BF, et al. Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy. Cancer Res 2006;66:9698-704.
35. Airley R, Loncaster J, Davidson S, et al. Glucose transporter Glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 2001;7:928-34.
36. Batchelor TT, Sorensen AG, di Tomaso E, et al. A2D2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95.
37. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002;94:883-93.
38. Tuettenberg J, Friedel C, Vajkoczy P. Angiogenesis in malignant glioma - a target for antitumor therapy? Crit Rev Oncol Hematol 2006;59:181 -93.
39. Rini Bl. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 2007;13:1098-106.
40. Jubb AM, Oates AJ, Holden S, Koeppen H. Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 2006;6:626-35.
41. Beecken WD, Fernandez A, Joussen AM, et al. Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice. J Natl Cancer Inst 2001;93:382-7.
42. Fenton BM, Paoni SF, Grimwood BG, Ding I. Disparate effects of endostatin on tumor vascular perfusion and hypoxia in two murine mammary carcinomas. Int J Radiat Oncol Biol Phys 2003;57:1038-46.
43. Fenton BM, Paoni SF, Ding I. Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors. Radiother Oncol 2004:72:221 -30.
44. Segers J, Fazio VD, Ansiaux R, et al. Potentiation of cyclophosphamide chemotherapy using the antiangiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature. Cancer Lett 2006;244: 129-35.
45. NakaharaT, Norberg SM, Shalinsky DR, Hu-Lowe DD, McDonald DM. Effect of inhibition of vascular endothelial growth factor signaling on distribution of ex-travasated antibodies in tumors. Cancer Res 2006;66: 1434-45.
46. Fenton BM, Paoni SF. The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature. Cancer Res 2007;67:9921 -8.
47. Huber PE, Bischof M, Jenne J, et al. Trimodal cancer treatment: beneficial effects of combined antiangio-genesis, radiation, and chemotherapy. Cancer Res 2005;65:3643-55.
48. Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003;63:4342-6.